HCPCS Level II code J9171 designates a 1 mg unit of docetaxel, a widely used intravenous chemotherapeutic agent for multiple cancer indications. Nationally, this billing code matters because it standardizes reporting for dosing units of a high-cost oncology drug, informs reimbursement workflows across payers, and impacts drug utilization tracking and oncology payment models.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for docetaxel dosing and administration, the typical settings where J9171 is billed, and what to expect in payer coverage patterns. The publication summarizes benchmark metrics and payment considerations, highlights relevant policy updates affecting chemotherapy billing and unitization of drugs, and provides practical coding context for service lines that bill infusion drugs.

This summary is written for a national audience and focuses on coding, clinical service context, and payer coverage scope. Data not available in the input will be noted where applicable in the full publication.